Among the 104 patients (KRAS-mutant NSCLC is mainly adenocarcinoma, accounting for 95.2%) who were assessed for co-occurring genomic alterations, efficacy was seen in the subgroups with mutated STK11, KEAP1, or TP53. The gene discussed is STK11; the disease is non-small cell lung carcinoma.